Assembly Biosciences(NASDAQ) ASMB

Assembly Biosciences makes medicines to treat serious viral infections. These drugs help people suffering from painful and long-term diseases. The company creates oral pills to replace daily injections.

What Does Assembly Build?

• Herpes Simplex Treatments: Long-acting inhibitors (HPIs) that block essential viral enzymes to prevent painful skin lesions and virus transmission.
• Hepatitis Delta Inhibitor: Oral pill designed to block the entry of the virus into liver cells to prevent severe scarring.
• Capsid Assembly Modulators: Next-generation medicines for hepatitis B (HBV) that disrupt how the virus builds its protective outer shell.
• Transplant Virus Defense: Broad-spectrum drugs meant to protect vulnerable patients from multiple viruses after receiving an organ transplant.

Recent Moves and Big Partnerships

• Formed a major antiviral collaboration with Gilead Sciences, Inc. in October 2023.
• Gilead Sciences, Inc. exercised its option in December 2025 to license the herpes program after positive clinical results.
• Transitioned development to ABI-7272 in October 2025 to target viruses that affect transplant patients.
• Started a structured process in March 2026 to find new partners for the ABI-4334 hepatitis B program.

What Sets the Science Apart?

The company relies on a leadership team that has helped develop over 15 approved antiviral drugs. Its research focuses on creating potent oral pills that are easier for patients to take than current injectable therapies.

Tracking the Financial Turnaround

• Revenue reached $42.5 million in Q4 2025, up 477.3% from the same period the previous year.
• Net income turned positive at $22.1 million in Q4 2025, compared to a loss of $10.3 million in Q4 2024.
• Free cash flow hit $14.2 million in Q4 2025, an improvement from a $407,000 loss in the prior year.
• Market capitalization grew to $381.3 million by Q4 2025, a 267.2% increase year-over-year.

Bottom Line

Assembly has evolved from a research-focused firm into a clinical-stage partner for major global pharmaceutical companies. The shift to positive cash flow and the licensing of its herpes program mark a new phase in its growth.